natgillin/translations-raw huggingface dataset:
Zoledronic acid Mylan must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronic acid Mylan’i võivad manustada ainult bisfosfonaatide intravenoosse, st veeni kaudu, manustamise koolituse läbinud tervishoiutöötajad.
Zoledronic acid Mylan must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledronic acid Mylan’i võivad patsientidele määrata ja manustada ainult intravenoosse bisfosfonaadi manustamises kogenud tervishoiutöötajad.
Zoledronic acid Mylan zoledronic acid
Zoledronic acid Mylan zoledroonhape
Zoledronic acid recommended dose*
Zoledroonhape medac soovitatav annus
Zoledronic acid recommended dose*
Zoledroonhape soovitatav annus
Zoledronic acid recommended dose*
Zoledroonhappe soovitatav annus
Zoledronic acid should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Tuleb olla ettevaatlik zoledroonhappe samaaegsel kasutamisel koos teiste ravimitega, mis võivad halvendada neerufunktsiooni (vt lõik 4.5).
Zoledronic acid should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Zoledroonhappe samaaegsel kasutamisel koos teiste ravimitega, mis võivad halvendada neerufunktsiooni tuleb olla ettevaatlik (vt lõik 4.5).
Zoledronic acid should not be used during pregnancy.
Zoledroonhape’t ei tohi kasutada raseduse ajal.
Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56 %) and independent of the concentration of zoledronic acid.
Zoledroonhape seondub plasmavalkudega vähesel määral (umbes 56%) ja see ei sõltu zoledroonhappe kontsentratsioonist.
Zoledronic acid shows no affinity for the cellular components of blood and plasma protein binding is low (approximately 56%) and independent of the concentration of zoledronic acid.
Zoledroonhape seondub plasmavalkudega vähesel määral (umbes 56%) ja see ei sõltu zoledroonhappe kontsentratsioonist.
Zoledronic acid Teva 4 mg/100 ml solution for infusion
Zoledronic acid Teva 4 mg/100 ml infusioonilahus
Zoledronic acid Teva 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Zoledronic acid Teva 4 mg/100 ml infusioonilahus on koheselt kasutamiseks valmis ja normaalse neerufunktsiooniga patsientidele võib seda manustada kohe, ilma edasise töötlemiseta.
Zoledronic acid Teva 4 mg/100 ml solution for infusion must not be mixed with other infusion solutions and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic acid Teva 4 mg/100 ml infusioonilahust ei tohi segada teiste infusioonilahustega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonisüsteemi kaudu.
Zoledronic acid Teva 4 mg/100 ml solution for infusion should be given as a single intravenous infusion in no less than 15 minutes.
Zoledronic acid Teva 4 mg/100 ml infusioonilahus tuleb manustada ühe intravenoosse infusioonina vähemalt 15 minuti kestel.
Zoledronic acid Teva 4 mg/100 ml solution for infusion Zoledronic acid
Zoledronic acid Teva 4 mg/100 ml infusioonilahus Acidum zoledronicum
Zoledronic Acid Teva 4 mg/5 ml concentrate for solution for infusion
Zoledronic acid Teva 4 mg/5 ml infusioonilahuse kontsentraat
Zoledronic acid Teva 4mg/5ml concentrate for solution for infusion and Zoledronic acid teva 4mg/100ml solution for infusion
Zoledronic acid Teva 4 mg/5 ml infusioonilahuse kontsentraat ja Zoledronic acid Teva 4 mg/100 ml infusioonilahus
Zoledronic Acid Teva 4mg/5ml concentrate for solution for infusion only
Zoledronic acid Teva 4 mg/5 ml infusioonilahuse kontsentraat
Zoledronic Acid Teva can be given to people aged 65 years and over.
Zoledronic acid Teva’t võivad kasutada ka 65-aastased ja vanemad patsiendid.
Zoledronic Acid Teva concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronic acid Teva kontsentraati ei tohi segada kaltsiumi või teisi bivalentseid katioone sisaldavate infusioonilahustega, nt Ringeri laktaatlahusega ja seda tuleb manustada ühe intravenoosse lahusena eraldi infusioonisüsteemi kaudu.
Zoledronic acid Teva contains 15.6 mmol (or 359.6 mg) sodium per dose.
Zoledronic acid Teva sisaldab 15,6 mmol (või 359,6 mg) naatriumi annuses.
Zoledronic acid Teva contains 15.6 mmol (or 359.6 mg) sodium per vial
Zoledronic acid Teva sisaldab 15,6 mmol (ehk 359,6 mg) naatriumi viaali kohta.
Zoledronic acid Teva Generics 5 mg solution for infusion in bags
Zoledronic acid Teva Generics 5 mg infusioonilahus kotis
Zoledronic acid Teva Generics 5 mg solution for infusion in bags is ready for use.
Zoledronic acid Teva Generics 5 mg kasutamisvalmis infusioonilahus kottides.
Zoledronic acid Teva Generics 5 mg solution for infusion in bottles
Zoledronic acid Teva Generics 5 mg infusioonilahus pudelis
Zoledronic acid Teva Generics 5 mg solution for infusion in bottles zoledronic acid
Zoledronic acid Teva Generics 5 mg infusioonilahus pudelis Zoledroonhape (Acidum zoledronicum)
Zoledronic acid Teva Generics 5 mg solution for infusion zoledronic acid
Zoledronic acid Teva Generics 5 mg infusioonilahus Zoledroonhape (Acidum zoledronicum)
Zoledronic acid Teva Generics contains sodium
Zoledronic acid Teva Generics sisaldab naatriumi
Zoledronic acid Teva Generics contains the active substance zoledronic acid.
Zoledronic acid Teva Generics’i toimeaine on zoledroonhape.
Zoledronic acid Teva Generics has no or negligible influence on the abililty to drive and use machines.
Zoledroonhappel ei ole või on ebaoluline toime autojuhtimise ja masinate käsitsemise võimele.
Zoledronic acid Teva Generics has no or negligible influence on the ability to drive and use machines.
Zoledronic acid Teva Generics’il ei ole või on ebaoluline toime autojuhtimise ja masinate käsitsemise võimele.
Zoledronic acid Teva Generics is a clear and colourless solution for infusion.
Zoledronic acid Teva Generics on selge ja värvitu infusioonilahus.
Zoledronic acid Teva Generics is a ‘generic medicine’.
Zoledronic acid Teva Generics on geneeriline ravim.
Zoledronic acid Teva Generics is also used in patients who have recently broken their hip in a minor trauma such as a fall and therefore are at risk of subsequent bone breaks.
Zoledronic acid Teva Generics’it kasutatakse ka patsientidel, kellel on hiljuti väikse trauma, näiteks kukkumise tagajärjel tekkinud reieluu proksimaalse osa murd ning kellel seetõttu on risk järgnevateks luumurdudeks.
Zoledronic acid Teva Generics is also used to treat Paget’s disease of the bone in adults.
Ravimit Zoledronic acid Teva Generics kasutatakse ka luu Pageti tõve raviks täiskasvanutel.
Zoledronic acid Teva Generics is not recommended for anyone under 18 years of age.
Zoledronic acid Teva Generics’it ei soovitata alla 18 aastastele isikutele.
Zoledronic acid Teva Generics is supplied in multipacks containing 5 or 10 bags.
Zoledronic acid Teva Generics’it turustatakse hulgipakendina, milles on 5 või 10 kotti.
Zoledronic acid Teva Generics is supplied in packs of 1, 5 or 10 bottles.
Zoledronic acid Teva Generics’it turustatakse pakendis, milles on 1, 5 või 10 pudelit.
Zoledronic acid Teva Generics may also cause other side effects
Zoledronic acid Teva Generics võib põhjustada ka teisi kõrvaltoimeid
Zoledronic acid Teva Generics must not be mixed or given intravenously with any other medicinal product and must be given through a separate vented infusion line at a constant infusion rate.
Zoledronic acid Teva Generics’it ei tohi segada või manustada intravenoosselt mistahes teise ravimiga ning seda tuleb manustada püsiva infusioonikiirusega eraldi ventileeritava infusioonisüsteemi kaudu.
Zoledronic acid Teva Generics should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Zoledroonhappe samaaegsel kasutamisel koos teiste ravimitega, mis võivad halvendada neerufunktsiooni tuleb olla ettevaatlik (vt lõik 4.5).
Zoledronic acid Teva Generics with food and drink
Zoledronic acid Teva Generics koos toidu ja joogiga
Zoledronic acid Teva Generics works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.
Zoledronic acid Teva Generics’i toimel muutub luu modelleerumisprotsess tagasi normaalseks tagades normaalse luu tekke ja luu tugevus taastub.
Zoledronic acid Teva is a ‘generic medicine’.
Zoledronic acid Teva on geneeriline ravim.
Zoledronic acid Teva is contraindicated in breast-feeding women (see section 4.3).
Rinnaga toitmise ajal on Zoledronic acid Teva vastunäidustatud (vt lõik 4.3).
Zoledronic Acid Teva is not recommended for use in adolescents and children below the age of 18 years.
Zoledronic acid Teva’t ei ole soovitatav kasutada alla 18-aastastel lastel ja noorukitel.
Zoledronic Acid Teva is supplied as a concentrate for solution for infusion.
Zoledronic acid Teva’t turustatakse infusioonilahuse kontsentraadina.
Zoledronic acid Teva is supplied as a solution for infusion.
Zoledronic acid Teva’t turustatakse infusioonilahusena.
Zoledronic acid Teva is supplied as packs containing 1, 4 or 10 bottles.
Zoledronic acid Teva’t turustatakse pakendites, mis sisaldavad 1, 4 või 10 pudelit.
Zoledronic Acid Teva is supplied as packs containing 1, 4 or 10 vials.
Zoledronic acid Teva’t turustatakse pakendites, mis sisaldavad 1, 4 või 10 viaali.
Zoledronic acid Teva must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledronic acid Teva’t võivad patsientidele määrata ja manustada ainult intravenoosse bisfosfonaadi manustamises kogenud tervishoiutöötajad.
Zoledronic acid Teva Pharma (5 mg in 100 ml ready-to-infuse solution) is administered via a vented infusion line and given at a constant infusion rate.
Zoledronic acid Teva Pharma’t (5 mg 100 ml-s manustamisvalmis infusioonilahuses) manustatakse antud püsiva infusioonikiirusega ventileeritava infusioonisüsteemi kaudu.
Zoledronic acid Teva Pharma 5 mg solution for infusion in bags
Zoledronic acid Teva Pharma 5 mg infusioonilahus kotis
Zoledronic acid Teva Pharma 5 mg solution for infusion in bags is ready for use.
Zoledronic acid Teva Pharma 5 mg infusioonilahus kotis on kasutamiseks valmis.
Zoledronic acid Teva Pharma 5 mg solution for infusion in bottles
Zoledronic acid Teva Pharma 5 mg infusioonilahus pudelis
Zoledronic acid Teva Pharma 5 mg solution for infusion in bottles zoledronic acid
Zoledronic acid Teva Pharma 5 mg infusioonilahus Acidum zoledronicum
Zoledronic acid Teva Pharma 5 mg solution for infusion is ready for use.
Zoledronic acid Teva Pharma 5 mg infusioonilahus on kasutamiseks valmis.
Zoledronic acid Teva Pharma 5 mg solution for infusion zoledronic acid
Zoledronic acid Teva Pharma 5 mg infusioonilahus Acidum zoledronicum
Zoledronic acid Teva Pharma contains sodium
Zoledronic acid Teva Pharma sisaldab naatriumi
Zoledronic acid Teva Pharma contains the same active substance found in Zometa (zoledronic acid), used for oncology indications, and a patient being treated with Zometa should be not be treated with Zoledronic acid Teva Pharma.
Zoledronic acid Teva Pharma sisaldab sama toimeainet nagu Zometa (zoledroonhape), mida kasutatakse onkoloogilistel näidustustel ja patsienti, keda ravitakse Zometa’ga ei tohi ravida Zoledronic acid Teva Pharma’ga.
Zoledronic acid Teva Pharma contains the same active substance found in Zometa (zoledronic acid), used for oncology indications, and a patient being treated with Zometa should not be treated with Zoledronic acid Teva Pharma.
Zoledronic acid Teva Pharma sisaldab sama toimeainet nagu Zometa (zoledroonhape), mida kasutatakse onkoloogilistel näidustustel ja patsienti, keda ravitakse Zometa’ga ei tohi ravida Zoledronic acid Teva Pharma’ga.
Zoledronic acid Teva Pharma has no or negligible influence on the ability to drive and use machines.
Zoledronic acid Teva Pharma’l ei ole või on ebaoluline toime autojuhtimise ja masinate käsitsemise võimele.
Zoledronic acid Teva Pharma is a clear and colourless solution.
Zoledronic acid Teva Pharma on selge ja värvitu lahus.
Zoledronic acid Teva Pharma is a ‘generic medicine’.
Zoledronic acid Teva Pharma on geneeriline ravim.
Zoledronic acid Teva Pharma is also used in patients who have recently broken their hip in a minor trauma such as a fall and therefore are at risk of subsequent bone breaks.
Zoledronic acid Teva Pharma’t kasutatakse ka patsientidel, kellel on hiljuti väikse trauma, näiteks kukkumise tagajärjel tekkinud reieluu proksimaalse osa murd ning kellel seetõttu on risk järgnevateks luumurdudeks.
Zoledronic acid Teva Pharma is also used to treat Paget’s disease of the bone in adults.
Ravimit Zoledronic acid Teva Pharma kasutatakse ka Pageti luutõve raviks täiskasvanutel.
Zoledronic acid Teva Pharma is not recommended for anyone under 18 years of age.
Zoledronic acid Teva Pharma’t ei soovitata alla 18-aastastele isikutele.
Zoledronic acid Teva Pharma is not recommended in women of childbearing potential.
Fertiilses eas naistel ei ole Zoledronic acid Teva Pharma’t soovitatav kasutada.
Zoledronic acid Teva Pharma is supplied in multipacks containing 5 or 10 bags (5 bags of 100 ml or 10 bags of 100 ml).
Zoledronic acid Teva Pharma on saadaval hulgipakendis, milles on 5 või 10 kotti (5 x 100 ml kotti või 10 x 100 ml kotti).
Zoledronic acid Teva Pharma is supplied in packs of 1, 5 or 10 bottles.
Zoledronic acid Teva Pharma on saadaval pakendites, milles on kas 1, 5 või 10 pudelit.
Zoledronic acid Teva Pharma may also cause other side effects
Zolderonic acid Teva Pharma võib põhjustada ka teisi kõrvaltoimeid
Zoledronic acid Teva Pharma may also cause other side effects
Zoledronic acid Teva Pharma võib põhjustada ka teisi kõrvaltoimeid
Zoledronic acid Teva Pharma must not be mixed or given intravenously with any other medicinal product and must be given through a separate vented infusion line at a constant infusion rate.
Zoledronic acid Teva Pharma’t ei tohi segada või manustada intravenoosselt mistahes teise ravimiga ning seda tuleb manustada püsiva infusioonikiirusega eraldi ventileeritava infusioonisüsteemi kaudu.
Zoledronic acid Teva Pharma should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Zoledronic acid Teva Pharma samaaegsel kasutamisel koos teiste ravimitega, mis võivad halvendada neerufunktsiooni, tuleb olla ettevaatlik (vt lõik 4.5).
Zoledronic acid Teva Pharma with food and drink
Zoledronic acid Teva Pharma koos toidu ja joogiga
Zoledronic acid Teva Pharma works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.
Zoledronic acid Teva Pharma toimel luu modelleerumisprotsess muutub tagasi normaalseks tagades normaalse luutekke ja luu tugevus taastub.
Zoledronic Acid Teva should not be used during pregnancy.
Zoledronic acid Teva’t ei tohi kasutada raseduse ajal.
Zoledronic acid Teva treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Raske neerukahjustusega TIH patsientidel võib ravi Zoledronic acid Teva’ga alustada vaid pärast võimaliku riski/eeldatava kasu suhte hindamist.
Zoledronic Acid Teva treatment should be resumed at the same dose as that given prior to treatment interruption.
Ravi Zoledronic acid Teva’ga tuleb jätkata sama annusega, mida kasutati enne ravi katkestamist.
Zoledronic acid treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment.
Raske neerupuudulikkusega TIH patsientidel võib ravi zoledroonhappe’ga alustada vaid pärast võimaliku riski/eeldatava kasu suhte hindamist.
Zoledronic acid treatment rapidly reduced the rate of bone turnover from elevated post-menopausal levels with the nadir for resorption markers observed at 7 days, and for formation markers at
Ravi zoledroonhappega vähendas kiiresti luukoe ringlust kõrgenenud postmenopausaalselt tasemelt täheldatud madalaimale resorptsioonimarkerite tasemele 7. päeval ja formatsioonimarkerite tasemele
Zoledronic acid treatment should be resumed at the same dose as that given prior to treatment interruption.
Ravi zoledroonhappe’ga tuleb jätkata sama annusega, mida kasutati enne ravi katkestamist.
Zoledronic acid treatment should be resumed at the same dose as that prior to treatment interruption.
Ravi zoledroonhappega tuleb jätkata sama annusega, mida kasutati enne ravi katkestamist.
Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation.
Zoledroonhappe potentsiaali tekitada kõrvaltoimeid fertiilsusele hinnati rottidel vanem- ja F1- põlvkonnas.
Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget's disease of the bone (median serum alkaline phosphatase level 2.6–3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Zoledroonhapet uuriti radiograafilise uuringuga kinnitatud, mõõduka kuni keskmise Paget’i luutõvega (seerumi alkaalse fosfataasi keskmine tase uuringu alguses 2,6…3 korda üle ea-spetsiifilise ülemise normi piiri) nais- ja meessoost patsientidel vanuses üle 30 aasta.
Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget’s disease of the bone (median serum alkaline phosphatase level 2.6-3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Zoledroonhapet uuriti radiograafilise uuringuga kinnitatud, mõõduka kuni keskmise Pageti luutõvega (seerumi alkaalse fosfataasi keskmine tase uuringu alguses 2,6…3 korda üle ea-spetsiifilise ülemise normi piiri) nais- ja meessoost patsientidel vanuses üle 30 aasta.
Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget’s disease of the bone (median serum alkaline phosphatase level 2.6-3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Zoledroonhapet uuriti radiograafilise uuringuga kinnitatud, mõõduka kuni keskmise Paget’i luutõvega (seerumi alkaalse fosfataasi keskmine tase uuringu alguses 2,6…3,0 korda üle ea-spetsiifilise ülemise normi piiri) nais- ja meessoost patsientidel vanuses üle 30 aasta.
Zoledronic acid was teratogenic in the rat at subcutaneous doses ≥ 0.2 mg/kg.
Zoledroonhape osutus teratogeenseks kasutatuna rottidel subkutaanselt annuses 0,2 mg/kg.
Zoledronic acid, used as indicated in sections 4.1 and 4.2, has been associated with reports of renal dysfunction.
Zoledroonhape, kasutatuna vastavalt näidustustele, mis on märgitud lõikudes 4.1 ja 4.2, võib halvendada neerufunktsiooni.
ZOLVIX 25 mg/ml oral solution for sheep
ZOLVIX 25 mg/ml suukaudne lahus lammastele
ZOLVIX 25 mg/ml oral solution for sheep Monepantel
ZOLVIX 25 mg/ml suukaudne lahus lammastele Monepanteel
ZOLVIX oral solution is a broad spectrum anthelmintic for the treatment and control of gastro- intestinal nematode infections and associated diseases in sheep including lambs, hoggets, breeding rams and ewes.
ZOLVIX suukaudne lahus on laiaspektriline antihelmintikum seedetrakti nematoodinfektsioonide ja nendega seostuvate haiguste raviks ja profülaktikaks lammastel, sh talledel, jääradel, suguloomadel ja emasloomadel.
Zomarist
Kokkuvõte üldsusele
Zomarist 50 mg/1000 mg film-coated tablets vildagliptin/metformin hydrochloride
Zomarist 50 mg/1000 mg õhukese polümeerikattega tabletid vildagliptiin/metformiinvesinikkloriid
Zomarist 50 mg/850 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “SEH” on the other.
Zomarist 50 mg/850 mg õhukese polümeerikattega tabletid on kollased, ovaalsed tabletid, mille ühel küljel on kiri „NVR” ja teisel „SEH”.
Zomarist 50 mg/850 mg film-coated tablets vildagliptin/metformin hydrochloride
Zomarist 50 mg/850 mg õhukese polümeerikattega tabletid vildagliptiin/metformiinvesinikkloriid
Zomarist is available in packs containing 10, 30, 60, 120, 180 or 360 film-coated tablets and in multi- packs containing 120 (2x60), 180 (3x60) or 360 (6x60) film-coated tablets.
Zomarist õhukese polümeerikattega tablette on pakendis 10, 30, 60, 120, 180 või 360 tk ja multipakendis 120 (2x60), 180 (3x60) või 360 (6x60) õhukese polümeerikattega tabletti.
Zomarist is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.
Zomarist on näidustatud kombinatsioonis sulfonüüluureaga (nt kolmikkombinatsioonravi) lisaks dieedile ja füüsilisele koormusele täiskasvanud patsientidel, kellel metformiini ja sulfonüüluureaga ei ole saavutatud piisavat kontrolli.
Zomarist is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Zomarist on näidustatud täiskasvanud patsientide raviks, kellel metformiini suukaudse monoteraapia maksimaalse talutava annusega ei ole saavutatud veresuhkru sisalduse piisavat vähenemist või kes juba saavad vildagliptiini ja metformiini kombinatsiooni eraldi tablettidena.
Zomarist is indicated in the treatment of type 2 diabetes mellitus:
Zomarist on näidustatud II tüüpi suhkurtõve raviks:
Zomarist is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Zomarist on näidustatud glükeemilise kontrolli parandamiseks kolmikkombinatsioonravis koos insuliiniga lisaks dieedile ja füüsilisele koormusele täiskasvanud patsientidel, kellel stabiilses annuses insuliin ja metformiin üksinda ei taga piisavat glükeemilist kontrolli.
Zomarist is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Zomarist on näidustatud glükeemilise kontrolli parandamiseks kolmikkombinatsioonravis koos insuliiniga lisaks dieedile ja füüsilisele täiskasvanud koormusele patsientidel, kellel stabiilses annuses insuliin ja metformiin üksinda ei taga piisavat glükeemilist kontrolli.
Zomarist is not recommended for use in children and adolescents (< 18 years).
Zomarist’i ei soovitata kasutada lastel ja noorukitel (vanus < 18 aasta).
Zomarist is used to treat adult patients with type 2 diabetes.
Zomarist’i kasutatakse II tüüpi suhkurtõve raviks täiskasvanutel.
Zomarist may be initiated at either the 50 mg/850 mg or 50 mg/1000 mg tablet strength twice daily, one tablet in the morning and the other in the evening.
Zomarist-ravi võib alustada kas 50 mg/850 mg või 50 mg/1000 mg tabletitugevusega kaks korda päevas, üks tablett hommikul ja teine õhtul.
Zomarist should not be used during pregnancy.
Zomarist’i ei tohi kasutada raseduse ajal.
Zomarist should not be used in patients with creatinine clearance < 60 ml/min (see sections 4.3, 4.4 and 5.2).
Zomarist’i ei tohi kasutada patsientidel kreatiniini kliirensiga < 60 ml/min (vt lõigud 4.3, 4.4 ja 5.2).
Zomarist should not be used in patients with hepatic impairment, including those with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN) (see sections 4.3, 4.4 and 4.8).
Zomarist’i ei tohi kasutada maksakahjustusega patsientidel, kaasa arvatud nendel patsientidel, kel ravieelne alaniinaminotransferaasi (ALAT) või aspartaataminotransferaasi (ASAT) väärtus on > 3x üle normivahemiku ülempiiri (ULN) (vt lõigud 4.3, 4.4 ja 4.8).
Zomarist with alcohol
Zomarist’i koos alkoholiga